Cargando…

Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model

Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanco-Blázquez, Virginia, Báez-Díaz, Claudia, Sánchez-Margallo, Francisco Miguel, González-Bueno, Irene, Martín, Helena, Blázquez, Rebeca, Casado, Javier G., Usón, Alejandra, Solares, Julia, Palacios, Itziar, Steendam, Rob, Crisóstomo, Verónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960949/
https://www.ncbi.nlm.nih.gov/pubmed/36826582
http://dx.doi.org/10.3390/jcdd10020086
_version_ 1784895634862505984
author Blanco-Blázquez, Virginia
Báez-Díaz, Claudia
Sánchez-Margallo, Francisco Miguel
González-Bueno, Irene
Martín, Helena
Blázquez, Rebeca
Casado, Javier G.
Usón, Alejandra
Solares, Julia
Palacios, Itziar
Steendam, Rob
Crisóstomo, Verónica
author_facet Blanco-Blázquez, Virginia
Báez-Díaz, Claudia
Sánchez-Margallo, Francisco Miguel
González-Bueno, Irene
Martín, Helena
Blázquez, Rebeca
Casado, Javier G.
Usón, Alejandra
Solares, Julia
Palacios, Itziar
Steendam, Rob
Crisóstomo, Verónica
author_sort Blanco-Blázquez, Virginia
collection PubMed
description Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administration of HGF-loaded extended release microspheres in an acute myocardial infarction (AMI) swine model. An IC infusion of 5 × 10(6) HGF-loaded microspheres (MS+HGF, n = 7), 5 × 10(6) placebo microspheres (MS, n = 7), or saline (SAL, n = 7) was performed two days after AMI. TIMI flow and Troponin I (TnI) values were assessed pre- and post-treatment. Cardiac function was evaluated with magnetic resonance imaging (cMR) before injection and at 10 weeks. Plasma cytokines were determined to evaluate the inflammatory profile and hearts were subjected to histopathological evaluation. Post-treatment coronary flow was impaired in five animals (MS+HGF and MS group) without significant increases in TnI. One animal (MS group) died during treatment. There were no significant differences between groups in cMR parameters at any time (p > 0.05). No statistically significant changes were found between groups neither in cytokines nor in histological analyses. The IC administration of 5 × 10(6) HGF-loaded-microspheres 48 h post-AMI did not improve cardiac function, nor did it decrease inflammation or cardiac fibrosis in this experimental setting.
format Online
Article
Text
id pubmed-9960949
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99609492023-02-26 Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model Blanco-Blázquez, Virginia Báez-Díaz, Claudia Sánchez-Margallo, Francisco Miguel González-Bueno, Irene Martín, Helena Blázquez, Rebeca Casado, Javier G. Usón, Alejandra Solares, Julia Palacios, Itziar Steendam, Rob Crisóstomo, Verónica J Cardiovasc Dev Dis Article Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administration of HGF-loaded extended release microspheres in an acute myocardial infarction (AMI) swine model. An IC infusion of 5 × 10(6) HGF-loaded microspheres (MS+HGF, n = 7), 5 × 10(6) placebo microspheres (MS, n = 7), or saline (SAL, n = 7) was performed two days after AMI. TIMI flow and Troponin I (TnI) values were assessed pre- and post-treatment. Cardiac function was evaluated with magnetic resonance imaging (cMR) before injection and at 10 weeks. Plasma cytokines were determined to evaluate the inflammatory profile and hearts were subjected to histopathological evaluation. Post-treatment coronary flow was impaired in five animals (MS+HGF and MS group) without significant increases in TnI. One animal (MS group) died during treatment. There were no significant differences between groups in cMR parameters at any time (p > 0.05). No statistically significant changes were found between groups neither in cytokines nor in histological analyses. The IC administration of 5 × 10(6) HGF-loaded-microspheres 48 h post-AMI did not improve cardiac function, nor did it decrease inflammation or cardiac fibrosis in this experimental setting. MDPI 2023-02-17 /pmc/articles/PMC9960949/ /pubmed/36826582 http://dx.doi.org/10.3390/jcdd10020086 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Blanco-Blázquez, Virginia
Báez-Díaz, Claudia
Sánchez-Margallo, Francisco Miguel
González-Bueno, Irene
Martín, Helena
Blázquez, Rebeca
Casado, Javier G.
Usón, Alejandra
Solares, Julia
Palacios, Itziar
Steendam, Rob
Crisóstomo, Verónica
Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model
title Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model
title_full Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model
title_fullStr Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model
title_full_unstemmed Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model
title_short Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model
title_sort intracoronary administration of microencapsulated hgf in a reperfused myocardial infarction swine model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960949/
https://www.ncbi.nlm.nih.gov/pubmed/36826582
http://dx.doi.org/10.3390/jcdd10020086
work_keys_str_mv AT blancoblazquezvirginia intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT baezdiazclaudia intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT sanchezmargallofranciscomiguel intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT gonzalezbuenoirene intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT martinhelena intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT blazquezrebeca intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT casadojavierg intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT usonalejandra intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT solaresjulia intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT palaciositziar intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT steendamrob intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel
AT crisostomoveronica intracoronaryadministrationofmicroencapsulatedhgfinareperfusedmyocardialinfarctionswinemodel